StreetInsider.com News Articles

TME Pharma Announces Date of Publication of Half Year Results and CEO Share Purchase

Mon, 22 Sep 2025 02:00:00 -0400

BERLIN--(BUSINESS WIRE)-- Regulatory News:

TME Pharma N.V. (Euronext Growth Paris: ALTME), a clinical-stage biotechnology company specializing in the development of novel therapies for cancer and eye diseases, announces today that its half year results will be published on 30 October 2025. The closed period for insiders of the Company will start next week, 30 days before the publication of the half-year results on October 30, 2025.

TME Pharma additionally announces that it has received notification that Diede Van Den Ouden, Chief Executive Officer and a Person Discharging Managerial Responsibilities ("PDMR"), has purchased an additional 300,000 ordinary shares in the

TME Pharma Announces Date of Publication of Half Year Results and CEO Share Purchase

Mon, 22 Sep 2025 02:00:00 -0400

BERLIN--(BUSINESS WIRE)-- Regulatory News:

TME Pharma Announces Date of Publication of Half Year Results and CEO Share Purchase

Mon, 22 Sep 2025 02:00:00 -0400

BERLIN--(BUSINESS WIRE)-- Regulatory News:

TME Pharma Announces Date of Publication of Half Year Results and CEO Share Purchase

Mon, 22 Sep 2025 02:00:00 -0400

BERLIN--(BUSINESS WIRE)-- Regulatory News:

TME Pharma Announces Date of Publication of Half Year Results and CEO Share Purchase

Mon, 22 Sep 2025 02:00:00 -0400

BERLIN--(BUSINESS WIRE)-- Regulatory News:

TME Pharma Announces Date of Publication of Half Year Results and CEO Share Purchase

Mon, 22 Sep 2025 02:00:00 -0400

BERLIN--(BUSINESS WIRE)-- Regulatory News:

TME Pharma Announces Date of Publication of Half Year Results and CEO Share Purchase

Mon, 22 Sep 2025 02:00:00 -0400

BERLIN--(BUSINESS WIRE)-- Regulatory News:

TME Pharma Announces Date of Publication of Half Year Results and CEO Share Purchase

Mon, 22 Sep 2025 02:00:00 -0400

BERLIN--(BUSINESS WIRE)-- Regulatory News:

TME Pharma Completes August Financing and Publishes Cash Position

Mon, 01 Sep 2025 02:00:00 -0400

TME Pharma has completed the fund raise announced last August 25th, receiving €500k in cash on August 28th in addition to the €1.7M raised end of May
Cash position €2.35M at end of August
TME will continue the process of making the organization as cost-efficient as possible
Lower cost basis model allows TME to attract financing to fund its development of novel therapies for cancer and eye diseases
Evaluation of crypto and crypto-related candidates ongoing, with no exposure yet

BERLIN--(BUSINESS WIRE)-- Regulatory News:

TME Pharma N.V. (Euronext Growth Paris: ALTME), a clinical-stage biotechnology company specializing in the development of novel therapies for

TME Pharma Completes August Financing and Publishes Cash Position

Mon, 01 Sep 2025 02:00:00 -0400

TME Pharma has completed the fund raise announced last August 25th, receiving €500k in cash on August 28th in addition to the €1.7M raised end of May
Cash position €2.35M at end of August
TME will continue the process of making the organization as cost-efficient as possible
Lower cost basis model allows TME to attract financing to fund its development of novel therapies for cancer and eye diseases
Evaluation of crypto and crypto-related candidates ongoing, with no exposure yet

BERLIN--(BUSINESS WIRE)-- Regulatory News:

TME Pharma N.V. (Euronext Growth Paris: ALTME), a clinical-stage biotechnology company specializing in the development of novel therapies for

TME Pharma Completes August Financing and Publishes Cash Position

Mon, 01 Sep 2025 02:00:00 -0400

TME Pharma has completed the fund raise announced last August 25th, receiving €500k in cash on August 28th in addition to the €1.7M raised end of May
Cash position €2.35M at end of August
TME will continue the process of making the organization as cost-efficient as possible
Lower cost basis model allows TME to attract financing to fund its development of novel therapies for cancer and eye diseases
Evaluation of crypto and crypto-related candidates ongoing, with no exposure yet

BERLIN--(BUSINESS WIRE)-- Regulatory News:

TME Pharma N.V. (Euronext Growth Paris: ALTME), a clinical-stage biotechnology company specializing in the development of novel therapies for

TME Pharma Completes August Financing and Publishes Cash Position

Mon, 01 Sep 2025 02:00:00 -0400

TME Pharma has completed the fund raise announced last August 25th, receiving €500k in cash on August 28th in addition to the €1.7M raised end of May
Cash position €2.35M at end of August
TME will continue the process of making the organization as cost-efficient as possible
Lower cost basis model allows TME to attract financing to fund its development of novel therapies for cancer and eye diseases
Evaluation of crypto and crypto-related candidates ongoing, with no exposure yet

BERLIN--(BUSINESS WIRE)-- Regulatory News:

TME Pharma N.V. (Euronext Growth Paris: ALTME), a clinical-stage biotechnology company specializing in the development of novel therapies for

TME Pharma Completes August Financing and Publishes Cash Position

Mon, 01 Sep 2025 02:00:00 -0400

TME Pharma has completed the fund raise announced last August 25th, receiving €500k in cash on August 28th in addition to the €1.7M raised end of May
Cash position €2.35M at end of August
TME will continue the process of making the organization as cost-efficient as possible
Lower cost basis model allows TME to attract financing to fund its development of novel therapies for cancer and eye diseases
Evaluation of crypto and crypto-related candidates ongoing, with no exposure yet

BERLIN--(BUSINESS WIRE)-- Regulatory News:

TME Pharma N.V. (Euronext Growth Paris: ALTME), a clinical-stage biotechnology company specializing in the development of novel therapies for

TME Pharma Completes August Financing and Publishes Cash Position

Mon, 01 Sep 2025 02:00:00 -0400

TME Pharma has completed the fund raise announced last August 25th, receiving €500k in cash on August 28th in addition to the €1.7M raised end of May
Cash position €2.35M at end of August
TME will continue the process of making the organization as cost-efficient as possible
Lower cost basis model allows TME to attract financing to fund its development of novel therapies for cancer and eye diseases
Evaluation of crypto and crypto-related candidates ongoing, with no exposure yet

BERLIN--(BUSINESS WIRE)-- Regulatory News:

TME Pharma N.V. (Euronext Growth Paris: ALTME), a clinical-stage biotechnology company specializing in the development of novel therapies for

TME Pharma Completes August Financing and Publishes Cash Position

Mon, 01 Sep 2025 02:00:00 -0400

TME Pharma has completed the fund raise announced last August 25th, receiving €500k in cash on August 28th in addition to the €1.7M raised end of May
Cash position €2.35M at end of August
TME will continue the process of making the organization as cost-efficient as possible
Lower cost basis model allows TME to attract financing to fund its development of novel therapies for cancer and eye diseases
Evaluation of crypto and crypto-related candidates ongoing, with no exposure yet

BERLIN--(BUSINESS WIRE)-- Regulatory News:

TME Pharma N.V. (Euronext Growth Paris: ALTME), a clinical-stage biotechnology company specializing in the development of novel therapies for

TME Pharma Completes August Financing and Publishes Cash Position

Mon, 01 Sep 2025 02:00:00 -0400

TME Pharma has completed the fund raise announced last August 25th, receiving €500k in cash on August 28th in addition to the €1.7M raised end of May
Cash position €2.35M at end of August
TME will continue the process of making the organization as cost-efficient as possible
Lower cost basis model allows TME to attract financing to fund its development of novel therapies for cancer and eye diseases
Evaluation of crypto and crypto-related candidates ongoing, with no exposure yet

BERLIN--(BUSINESS WIRE)-- Regulatory News:

TME Pharma N.V. (Euronext Growth Paris: ALTME), a clinical-stage biotechnology company specializing in the development of novel therapies for

TME Pharma to raise €500k through new bond issue and receives new notice of shareholding

Mon, 25 Aug 2025 02:00:00 -0400

TME Pharma is raising additional funds to accelerate the Company's fundamental activities and to increase its budget for its treasury investment strategy
TME Pharma has secured binding commitments for a new fund raising of a net amount of €500,000 in the form of regular bonds repayable in cash with a 9-month maturity
Private, non-listed warrants attached with an exercise price of €0.11, a 2,12% premium to the prior 10-day VWAP, could bring another €702,576 if exercised
Lead investor in May financing round has committed to investing a further €427,000 as part of this round
The lead investor informed the Company that it currently

TME Pharma to raise €500k through new bond issue and receives new notice of shareholding

Mon, 25 Aug 2025 02:00:00 -0400

TME Pharma is raising additional funds to accelerate the Company's fundamental activities and to increase its budget for its treasury investment strategy

TME Pharma has secured binding commitments for a new fund raising of a net amount of €500,000 in the form of regular bonds repayable in cash with a 9-month maturity

Private, non-listed warrants attached with an exercise price of €0.11, a 2,12% premium to the prior 10-day VWAP, could bring another €702,576 if exercised

Lead investor in May financing round has committed to investing a further €427,000 as part of this round

The lead investor informed the Company that it currently

TME Pharma to raise €500k through new bond issue and receives new notice of shareholding

Mon, 25 Aug 2025 02:00:00 -0400

TME Pharma is raising additional funds to accelerate the Company's fundamental activities and to increase its budget for its treasury investment strategy

TME Pharma has secured binding commitments for a new fund raising of a net amount of €500,000 in the form of regular bonds repayable in cash with a 9-month maturity

Private, non-listed warrants attached with an exercise price of €0.11, a 2,12% premium to the prior 10-day VWAP, could bring another €702,576 if exercised

Lead investor in May financing round has committed to investing a further €427,000 as part of this round

The lead investor informed the Company that it currently

TME Pharma to raise €500k through new bond issue and receives new notice of shareholding

Mon, 25 Aug 2025 02:00:00 -0400

TME Pharma is raising additional funds to accelerate the Company's fundamental activities and to increase its budget for its treasury investment strategy

TME Pharma has secured binding commitments for a new fund raising of a net amount of €500,000 in the form of regular bonds repayable in cash with a 9-month maturity

Private, non-listed warrants attached with an exercise price of €0.11, a 2,12% premium to the prior 10-day VWAP, could bring another €702,576 if exercised

Lead investor in May financing round has committed to investing a further €427,000 as part of this round

The lead investor informed the Company that it currently

TME Pharma to raise €500k through new bond issue and receives new notice of shareholding

Mon, 25 Aug 2025 02:00:00 -0400

TME Pharma is raising additional funds to accelerate the Company's fundamental activities and to increase its budget for its treasury investment strategy

TME Pharma has secured binding commitments for a new fund raising of a net amount of €500,000 in the form of regular bonds repayable in cash with a 9-month maturity

Private, non-listed warrants attached with an exercise price of €0.11, a 2,12% premium to the prior 10-day VWAP, could bring another €702,576 if exercised

Lead investor in May financing round has committed to investing a further €427,000 as part of this round

The lead investor informed the Company that it currently

TME Pharma to raise €500k through new bond issue and receives new notice of shareholding

Mon, 25 Aug 2025 02:00:00 -0400

TME Pharma is raising additional funds to accelerate the Company's fundamental activities and to increase its budget for its treasury investment strategy

TME Pharma has secured binding commitments for a new fund raising of a net amount of €500,000 in the form of regular bonds repayable in cash with a 9-month maturity

Private, non-listed warrants attached with an exercise price of €0.11, a 2,12% premium to the prior 10-day VWAP, could bring another €702,576 if exercised

Lead investor in May financing round has committed to investing a further €427,000 as part of this round

The lead investor informed the Company that it currently

TME Pharma to raise €500k through new bond issue and receives new notice of shareholding

Mon, 25 Aug 2025 02:00:00 -0400

TME Pharma is raising additional funds to accelerate the Company's fundamental activities and to increase its budget for its treasury investment strategy

TME Pharma has secured binding commitments for a new fund raising of a net amount of €500,000 in the form of regular bonds repayable in cash with a 9-month maturity

Private, non-listed warrants attached with an exercise price of €0.11, a 2,12% premium to the prior 10-day VWAP, could bring another €702,576 if exercised

Lead investor in May financing round has committed to investing a further €427,000 as part of this round

The lead investor informed the Company that it currently

TME Pharma to raise €500k through new bond issue and receives new notice of shareholding

Mon, 25 Aug 2025 02:00:00 -0400

TME Pharma is raising additional funds to accelerate the Company's fundamental activities and to increase its budget for its treasury investment strategy

TME Pharma has secured binding commitments for a new fund raising of a net amount of €500,000 in the form of regular bonds repayable in cash with a 9-month maturity

Private, non-listed warrants attached with an exercise price of €0.11, a 2,12% premium to the prior 10-day VWAP, could bring another €702,576 if exercised

Lead investor in May financing round has committed to investing a further €427,000 as part of this round

The lead investor informed the Company that it currently

TME Pharma Provides Update About Additional Strategy

Tue, 29 Jul 2025 12:25:00 -0400

BERLIN--(BUSINESS WIRE)-- Regulatory News:
TME Pharma N.V. (Euronext Growth Paris: ALTME), a clinical-stage biotechnology company specializing in the development of novel therapies for cancer and eye diseases, is pleased to share an update regarding its strategic repositioning.

Pursuing stable, cash-generating business opportunities to achieve positive operational cash flow at the holding company level

Leveraging tax loss carry forwards

Repositioning to enhance shareholder value creation, while maintaining the ultimate strategic focus on the development of NOX-A12 and NOX-E36 assets

Gained access to the crypto-markets via newly established crypto brokerage account

TME Pharma NV is currently a holding company. Management will now implement and